Y-Mabs Therapeutics Inc

NASDAQ:YMAB   10:59:00 AM EDT
14.61
-0.20 (-1.35%)
Products

Y-mAbs Announces FDA Acceptance Of Biologics License Application For Omblastys® For The Treatment Of Neuroblastoma For Priority Review

Published: 05/31/2022 13:34 GMT
Y-Mabs Therapeutics Inc (YMAB) - Y-mabs Announces FDA Acceptance of Biologics License Application for Omblastys® (omburtamab) for the Treatment of Neuroblastoma for Priority Review.